Mon compte


» » Etudes Cardiologie



Development of an optimized multimarker strategy

for early risk assessment of
patients with acute coronary syndromes





Lipoprotein-associated phospholipase A2
for early risk stratification in patients
with suspected acute coronary syndrome:
a multi-marker approach





Lipoprotein-Associated Phospholipase A2 Is an Independent
Marker for Coronary Endothelial Dysfunction in Humans







Lipoprotein-Associated Phospholipase A2 and Prognosis
After Myocardial Infarction in the Community







Utilisation des marqueurs cardiaques dans la maladie

coronarienne et l'insuffisance cardiaque chez l'adulte

en médecine ambulatoire





Lipoprotein-Associated Phospholipase A2: An Independent
Predictor of Coronary Artery Disease Events in Primary and
Secondary Prevention








Ou encore :




Lipoprotein-Associated Phospholipase A2 Protein Expression in the Natural Progression of Human Coronary Atherosclerosis




Local Production of Lipoprotein-Associated Phospholipase A2 and Lysophosphatidylcholine in the Coronary Circulation 



Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up



Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study




Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque



Lipoprotein-Associated Phospholipase A2 et évaluation du risque cardiaque